Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S; The New England Journal Of Medicine, 2007, vol. 357, issue 2, p 124, ISSN 15334406. ISBN 15334406.
Full Text Resources Located for this Citation